AGXT and primary hyperoxaluria type 1: In primary hyperoxaluria type 1 (PH1), insertion of the alanine–glyoxylate aminotransferase (AGXT) gene into the AAVS1 site of PH1 patient-derived iPSCs enabled stable AGXT expression both in iPSCs and differentiated hepatocyte-like cells, suggesting their potential use in autologous cell-based gene therapy for PH1 treatment [174].